/ALNOX.PA

ALNOX.PA Stock - NOXXON Pharma N.V.

Q: What is the analyst price target for ALNOX.PA?

Analyst price target information is not currently available for ALNOX.PA.

Q: What is ALNOX.PA's market cap?

Market capitalization information is not currently available for ALNOX.PA.

Healthcare|Biotechnology|PAR

$0.04+0.00%

+$0.00 (+0.00%) • Apr 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.05

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ALNOX.PA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.24

52W High$0.41

52W Low$0.04

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	$-1,029,000	$-982,000	$-959,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-12,947,000	$-5,350,000	$-857,000	$-3,975,000	$-3,706,000
Net Income	$-14,453,000	$-15,461,000	$-861,000	$-10,738,000	$-5,390,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-45.99	$-47.78	$-7.72	$-269.86	$-253.81

Company Overview

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

Visit Website